Cecile M Yelnik, Zeynep Belce Erton, Elodie Drumez, Dachi Cheildze, Danieli de Andrade, Ann Clarke, Maria G Tektonidou, Savino Sciascia, Jose Pardos-Gea, Vittorio Pengo, Guillermo Ruiz-Irastorza, H Michael Belmont, Chary Lopez Pedrera, Paul R Fortin, Denis Wahl, Maria Gerosa, Nina Kello, Flavio Signorelli, Tatsuya Atsumi, Lanlan Ji, Maria Efthymiou, D Ware Branch, Cecilia Nalli, Esther Rodriguez-Almaraz, Michelle Petri, Ricard Cervera, Hui Shi, Yu Zuo, Bahar Artim-Esen, Guillermo Pons-Estel, Rohan Willis, Megan R W Barber, Leslie Skeith, Maria Laura Bertolaccini, Hannah Cohen, Robert Roubey, Doruk Erkan
BACKGROUND: Long-term anticoagulant therapy is generally recommended for thrombotic antiphospholipid syndrome (TAPS) patients, however it may be withdrawn or not introduced in routine practice. OBJECTIVES: To prospectively evaluate the risk of thrombosis recurrence and major bleeding in non-anticoagulated TAPS patients, compared to anticoagulated TAPS, and secondly, to identify different features between those two groups. PATIENTS/METHODS: Using an international registry, we identified non-anticoagulated TAPS patients at baseline, and matched them with anticoagulated TAPS patients based on gender, age, type of previous thrombosis, and associated autoimmune disease...
December 20, 2023: Seminars in Arthritis and Rheumatism